Horizon Therapeutics plc News Releases https://ir.horizontherapeutics.com/ Horizon Therapeutics plc News Releases en Horizon Therapeutics plc Launches New Data-Driven Campaign to Reset the Dialogue on Gout https://ir.horizontherapeutics.com/news-releases/news-release-details/horizon-therapeutics-plc-launches-new-data-driven-campaign-reset -- Research that has redefined the trajectory and true impact of the disease underscores the campaign -- DUBLIN --(BUSINESS WIRE)--May 16, 2019-- Horizon Therapeutics plc (Nasdaq: HZNP) today announced the launch of Gout Lies , a data-driven campaign to reframe physician dialogue on the reality of Thu, 16 May 2019 08:00:00 -0400 Horizon Therapeutics plc News Releases 16146 Horizon Therapeutics plc Announces Tina Ventura as a Healthcare Businesswomen's Association 2019 Luminary https://ir.horizontherapeutics.com/news-releases/news-release-details/horizon-therapeutics-plc-announces-tina-ventura-healthcare DUBLIN --(BUSINESS WIRE)--May 9, 2019-- Horizon Therapeutics plc (Nasdaq: HZNP) announced today that Tina Ventura , senior vice president, investor relations, has been named a 2019 Healthcare Businesswomen's Association (HBA) Luminary. Tina will be honored today at the 30 th  annual Woman of the Thu, 09 May 2019 08:00:00 -0400 Horizon Therapeutics plc News Releases 16131 Horizon Therapeutics plc Reports Strong First-Quarter 2019 Results; Increases Full‐Year 2019 Net Sales and Adjusted EBITDA Guidance https://ir.horizontherapeutics.com/news-releases/news-release-details/horizon-therapeutics-plc-reports-strong-first-quarter-2019 -- First-Quarter 2019 Net Sales of $280.4 Million Increased 25 Percent; First-Quarter 2019 GAAP Net Loss of $32.9 Million ; Adjusted EBITDA of $88.4 Million -- -- Quarterly Orphan and Rheumatology Segment Net Sales Increased 8 Percent to $185.9 Million -- -- Increasing Full-Year 2019 Net Sales Wed, 08 May 2019 07:04:00 -0400 Horizon Therapeutics plc News Releases 16106 Horizon Therapeutics plc Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) https://ir.horizontherapeutics.com/news-releases/news-release-details/horizon-therapeutics-plc-reports-inducement-grants-under-nasdaq DUBLIN --(BUSINESS WIRE)--May 6, 2019-- Horizon Therapeutics plc (Nasdaq: HZNP) today announced that the compensation committee of its board of directors approved the grant on May 1, 2019 of inducement restricted stock units for an aggregate of 53,008 ordinary shares to 31 new employees. Mon, 06 May 2019 08:00:00 -0400 Horizon Therapeutics plc News Releases 16051 New Data from Phase 3 Teprotumumab Trial (OPTIC) Shows Dramatic Reduction in Proptosis, or Eye Bulging, the Main Cause of Morbidity in Active Thyroid Eye Disease (TED) https://ir.horizontherapeutics.com/news-releases/news-release-details/new-data-phase-3-teprotumumab-trial-optic-shows-dramatic -- Efficacy Demonstrated Across Measures Not Addressed by Current Therapies -- -- New Data at the 2019 American Association of Clinical Endocrinologists (AACE) Scientific and Clinical Congress Demonstrates Significant Proptosis Reduction and Improvement in Overall Response Rate -- DUBLIN Fri, 26 Apr 2019 14:00:00 -0400 Horizon Therapeutics plc News Releases 16006 Horizon Pharma plc and Gift of Adoption Announce a New Fund to Facilitate Global Adoptions of Children with Rare Diseases https://ir.horizontherapeutics.com/news-releases/news-release-details/horizon-pharma-plc-and-gift-adoption-announce-new-fund -- The #RAREis™ Adoption Fund fills a critical gap for families seeking to provide a permanent home for children living with critical medical needs -- DUBLIN --(BUSINESS WIRE)--Apr. 16, 2019-- Horizon Pharma plc (Nasdaq: HZNP) in partnership with Gift of Adoption today announced the creation of the Tue, 16 Apr 2019 08:00:00 -0400 Horizon Therapeutics plc News Releases 15956 Horizon Pharma plc to Present Results from its Phase 3 Teprotumumab Trial (OPTIC) at the 2019 American Association of Clinical Endocrinologists (AACE) Scientific and Clinical Congress https://ir.horizontherapeutics.com/news-releases/news-release-details/horizon-pharma-plc-present-results-its-phase-3-teprotumumab DUBLIN --(BUSINESS WIRE)--Apr. 12, 2019-- Horizon Pharma plc (Nasdaq: HZNP) today announced that it will present additional results from its Phase 3 confirmatory clinical trial (OPTIC) evaluating teprotumumab for the treatment of active thyroid eye disease (TED) at the 2019 American Association of Fri, 12 Apr 2019 08:00:00 -0400 Horizon Therapeutics plc News Releases 15951 Horizon Pharma plc Named One of the 2019 Best Workplaces in Health Care and Biopharma by FORTUNE and Great Place to Work® https://ir.horizontherapeutics.com/news-releases/news-release-details/horizon-pharma-plc-named-one-2019-best-workplaces-health-care - Company also awarded “Best Places to Work in Chicago” by Crain’s Chicago Business – DUBLIN --(BUSINESS WIRE)--Apr. 11, 2019-- Horizon Pharma plc (NASDAQ:HZNP) today announced it has been selected as one of the 2019 Best Workplaces in Health Care and Biopharma by  Great Place to Work® and  FORTUNE Thu, 11 Apr 2019 16:45:00 -0400 Horizon Therapeutics plc News Releases 15946 Horizon Pharma plc to Release First-Quarter 2019 Financial Resultsand Host Webcast on May 8, 2019 https://ir.horizontherapeutics.com/news-releases/news-release-details/horizon-pharma-plc-release-first-quarter-2019-financial DUBLIN--( BUSINESS WIRE )--Horizon Pharma plc (Nasdaq: HZNP) announced today that its first-quarter 2019 financial results will be released on Wednesday, May 8, 2019. Following the announcement, Horizon's management will host a live webcast at 8 a.m. Eastern Time to review the Company's financial Tue, 09 Apr 2019 07:00:00 -0400 Horizon Therapeutics plc News Releases 15991 Horizon Pharma plc Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) https://ir.horizontherapeutics.com/news-releases/news-release-details/horizon-pharma-plc-reports-inducement-grants-under-nasdaq-10 DUBLIN --(BUSINESS WIRE)--Apr. 4, 2019-- Horizon Pharma plc (Nasdaq: HZNP) today announced that the compensation committee of its board of directors approved the grant on April 1, 2019 of inducement restricted stock units for an aggregate of 48,477 ordinary shares to 14 new employees. Thu, 04 Apr 2019 16:05:00 -0400 Horizon Therapeutics plc News Releases 15916